AKT1 and neoplasm: Similarly, an inhibitor of phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, NVP-BEZ235, inhibited TME-specific signaling pathways such as IL4 and IL6/STAT3, resulting in suppression of angiogenesis, migration, and tumor invasiveness in MCL cells [33].